Navigation Links
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Date:7/24/2008

BRISBANE, Calif., July 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release second quarter 2008 financial results and provide a business update on Thursday, July 31, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 57393097. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57393097.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Jefferies Healthcare Conference
2. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
3. InterMune to Present at Citigroup Healthcare Conference
4. InterMune to Present at Bank of America Health Care Conference
5. InterMune to Present at Deutsche Bank Health Care Conference
6. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
7. Evotec Expands Collaboration With InterMune
8. InterMune to Present at the SIGnificant Options in Healthcare Conference
9. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
10. InterMune Announces Closing of Public Offering of Common Stock
11. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... PARK, N.C., Feb. 22, 2017  United Therapeutics Corporation ... financial results for the fourth quarter and year ... financial results reflect continued growth as net revenues ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... ability to develop and advance our growing product ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Liquid Biopsy System , a fully automated benchtop system for collecting intact circulating ... is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 ...
(Date:2/21/2017)... Chicago, IL (PRWEB) , ... ... ... launch of the Life -Sciences division, Treximo will pair its $200M operational ... class, results-based consulting and project management in areas affecting quality and operational ...
(Date:2/21/2017)... 2017  Lexus, a returning partner of the Amgen Tour ... exclusive automobile partner of the men,s and women,s events for the ... 2017 Amgen Tour of California will mark ... the best professional cycling teams in the world racing from Northern ... Amgen Breakaway from Heart Disease TM Women,s Race ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):